OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Marshall on ASCENDE-RT Trial for Prostate Cancer

January 13th 2016

David T. Marshall, MD, MS, professor, director, Medical Residency Program, Department of Radiation Oncology, Medical University of South Carolina, discusses the ASCENDE-RT trial, which compared dose-escalated external beam radiation therapy versus low-dose-rate brachytherapy for men with unfavorable-risk localized prostate cancer.

Dr. Burtness on Emerging Immunotherapies in Head and Neck Cancer

January 12th 2016

Barbara A. Burtness, MD, professor of Medicine (Medical Oncology), clinical research program leader, Head and Neck Cancers Program, co-director, Developmental Therapeutics Research Program, Yale Cancer Center, discusses emerging immunotherapies and ongoing clinical trials in head and neck cancer.

Dr. Steven Rosenberg on the Curative Potential of Adoptive Cell Therapy

January 8th 2016

Steven A. Rosenberg, MD, PhD, chief, Surgery Branch, senior investigator, head, Tumor Immunology Section, National Cancer Institute, explains advancements in adoptive cell therapy for the treatment of melanoma.

Dr. Komanduri on Emerging Therapies for Patients With Hematologic Malignancies

January 8th 2016

Krishna Komanduri, MD, professor of Medicine, Microbiology, and Immunology, director, Sylvester Adult Stem Cell Transplant Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses future treatments for patients with hematologic malignancies.

Dr. Moreau on Tourmaline-MM1 Study for Multiple Myeloma

January 7th 2016

Philippe Moreau, MD, head of Department of Hematology, Centre Hospitalier et Universitaire, Nantes, France, discusses the phase III Tourmaline-MM1 study for patients with relapsed/refractory multiple myeloma.

Dr. Formenti on Combining Radiotherapy With Immunotherapy in NSCLC

January 7th 2016

Silvia Formenti, MD, chair of Radiation Oncology at Weill Cornell Medical College and radiation oncologist-in-chief at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses combining radiotherapy with immunotherapy in non-small cell lung cancer (NSCLC).

Dr. Arlene Sharpe on the Role of the PD-1 Pathway

January 7th 2016

Arlene Sharpe, MD, PhD, immunology faculty member, Harvard Medical School, discusses the biology of the PD-1 pathway.

Dr. Swords on Anti-Tumor Effects of IMG-98 in AML

January 6th 2016

Ronan T. Swords, MD, discusses preclinical findings demonstrating that the small-molecule inhibitor IMG-98 effectively augments pro-differentiation effects of all-trans-retinoic acidâ€“based therapies in acute myeloid leukemia.

Dr. Murphy on Glioma Prognostic Factors in Younger Patients

January 6th 2016

Erin Murphy, MD, associate staff, Department of Radiation Oncology, Cleveland Clinic, discusses a study examining prognostic factors of patients with glioma.

Dr. Mamounas on Future of Surgical Treatments in Breast Cancer

January 5th 2016

Eleftherios P. Mamounas, MD, surgical oncologist, UF Health Cancer Center - Orlando Health, shares the future of surgical treatments for patients with breast cancer.

Dr. Goodman on Ongoing Clinical Trials in Radiation Oncology

January 5th 2016

Karyn A. Goodman, MD, radiation oncologist, professor in the Department of Radiation Oncology, University of Colorado Denver, discusses ongoing trials in the field of radiation oncology.

Dr. Luke on the Future of Combination Therapy in Melanoma

January 5th 2016

Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses what the future holds for combination therapies for patients with melanoma.

Dr. Hofmeister on Reolysin Combined With Carfilzomib for Multiple Myeloma

January 4th 2016

Craig Hofmeister, MD, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University, discusses a study that examined the efficacy of reolysin combined with carfilzomib in patients with relapsed multiple myeloma.

Dr. Pecora on RCCA's New Business and Science Approaches

January 1st 2016

Andrew L. Pecora, MD, FACP, CPE, chief innovations officer, professor, vice president of Cancer Services, John Theurer Cancer Center at Hackensack University Medical Center, president, Regional Cancer Care Associates (RCCA), LLC, discusses new business and science approaches RCCA has taken to better provide value-based care to patients.

Dr. Rizzo on Impact of Age on Survival Outcomes in MDS After HCT

December 31st 2015

J. Douglas Rizzo, MD, MS, assistant scientific professor, Center for International Blood and Marrow Transplant Research, professor of Medicine, Medical College of Wisconsin, discusses a study that examined if age affects survival outcomes in patients with myelodysplastic syndromes who receive a hematopoietic cell transplant.

Demmie Aguilar on Selecting a Clinical Trial Site

December 30th 2015

Demmie Aguilar, research coordinator, Clinical Research Division, Regional Cancer Care Associates, LLC, Central Jersey Division, discusses the qualities pharmaceutical companies look for when selecting a clinical trial site.

Dr. Lonial on Novel Mechanisms in Multiple Myeloma

December 29th 2015

Sagar Lonial, MD, chief medical officer at Winship Cancer Institute of Emory University, discusses novel mechanisms of agents used for the treatment of patients with multiple myeloma.

Dr. Wiesner on Importance of Genetic Testing for CRC

December 28th 2015

Georgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, discusses the importance of genetic testing for colorectal cancer.

Dr. Ciezki on Common Advanced Disease Sites in Patients

December 24th 2015

Jay Ciezki, MD, Department of Radiation Oncology, Cleveland Clinic, discusses an analysis of patients with various malignancies who commonly presented with advanced disease.

Dr. Wu on Possible Combinations With TAS-102 in CRC

December 23rd 2015

Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses potential combinations with TAS-102 for the treatment of patients with colorectal cancer.